I would think any potential acquirer is waiting to see whether or not the FDA will even accept their accelerated NDA for carfilzomib. Might be another IMGN scenario, except their results were much more impressive with fewer question marks surrounding their trial. See some info below
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.